US Edition
MariMed CEO Jon Levine on Q2 Results & Growth Strategy
Summary by The Dales Report
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MariMed CEO Jon Levine on Q2 Results & Growth Strategy
MariMed just delivered another quarter of positive cash flow, strong Adjusted EBITDA margins, and strategic market moves — and we’re sitting down with the CEO to unpack it all. Cannabis operator MariMed (OTCQX: MRMD) reported strong second-quarter 2024 results, delivering positive cash flow and sequential growth in both wholesale and retail operations. CEO John Levine joined the Trade To Black podcast to discuss the company’s performance, brand …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
